Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZZ06 in advanced solid tumors
NCT04412616Phase 1Recruiting
- Sponsor
- Changchun Intellicrown Pharmaceutical Co., Ltd.
- Start
- Sep 2020
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of ZZ06 in solid tumor (7 arms), sponsored by Changchun Intellicrown Pharmaceutical Co., Ltd. Primary endpoints: Incidence of Treatment-Emergent Adverse Events (TEAEs) and Dose Limiting Toxicities (DLTs) up to 36 weeks, Incidence of abnormal laboratory test results up to 36 weeks and 1 more. Started Sep 2020; status: recruiting.
02
Drugs
ZZ06
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04412616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04412616.